; and (iii) has a strong record of good manufacturing practices of active pharmaceutical ingredients; or (C) is a distributor or wholesaler of an eligible drug, in partnership with an entity that meets the requirements of subparagraph (A). (f) Reports to Congress Not later than 2 years after the date on which the first award is made under this section, and every 2 years thereafter, the Secretary shall submit a report to Congress detailing— (1) the list of drugs determined to be eligible drugs, as described in subsection (e)(2), and the rationale behind selecting each such drug; and (2) an update on the effectiveness of the program under this section, in a manner that does not compromise national security. (g) Authorization of appropriations To carry out this section, there is authorized to be appropriated $500,000,000 for fiscal year 2024. 3. GAO report Not later than 18 months after the date of enactment of this Act, the Comptroller General of the United States shall— (1) examine, such as through a survey or other means, excess or underutilized domestic manufacturing capacity for critical drugs and active pharmaceutical ingredients of such drugs, including capacity to manufacture different dosage forms, such as oral tablets and sterile injectable drugs, and the capacity to manufacture drugs with various characteristics, such as cytotoxic drugs and drugs requiring lyophilization; and (2) prepare and submit a report to the Committee on Homeland Security and Governmental Affairs and the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Homeland Security and the Committee on Energy and Commerce of the House of Representatives that— (A) includes— (i) the results of the survey under paragraph (1)